Details of the Drug Reposition

General Information of This Drug (ID: DMOVH1M)

Drug Name
Oxytetracycline   DMOVH1M
Synonyms
Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
18 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Yaws DISLTH3X N.A. Approved [1]
Typhus DISJ5JX1 N.A. Approved [1]
Trachoma DIS2WZUR N.A. Approved [1]
Syphilis DISJ73BS N.A. Approved [1]
Rocky mountain spotted fever DISFN72S N.A. Approved [1]
Rickettsialpox DISEMENW N.A. Approved [1]
Relapsing fever DISEA4L7 N.A. Approved [1]
Q fever DISK1S90 N.A. Approved [1]
Ornithosis DIS4YMZ8 N.A. Approved [1]
Lymphogranuloma venereum DIS0MMFT N.A. Approved [1]
Brucellosis DISEAYGH N.A. Approved [1]
Acute gonococcal epididymo-orchitis DISBF6L8 N.A. Approved [1]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [1]
Actinomycosis DIS7YFRP N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
Bronchitis DISBM6EQ CA20 Approved [1]
Pneumonia DIS8EF3M CA40 Approved [1]
Urinary tract infection DISMT6UV GC08 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute gonococcal endometritis DISZ8BW7 N.A. Withdrawn [3]
------------------------------------------------------------------------------------
2 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Granuloma inguinale DISRKXBH N.A. Discontinued in Phase 3 [4]
Pharyngitis DISSN548 CA02.Z Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial conjunctivitis DIST79FU N.A. Discontinued in Phase 1 [6]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sinusitis DISX5NCF CA0A.Z Investigative [1]
------------------------------------------------------------------------------------

References

1 Oxytetracycline FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 060634.
3 Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis
4 Autoimmunity in Inner Ear Disease
5 Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
6 MT2004-30: Tomotherapy for Solid Tumors